9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
Key Takeaways
- Adjuvant immunotherapy with anti-PD-1 monotherapy (pembrolizumab via KEYNOTE-716/KEYNOTE-054 or nivolumab via CheckMate 238) or dual targeted therapy with dabrafenib plus trametinib (COMBI-AD for BRAF V600E/K) for 1 year significantly reduces relapse risk in resected high-risk Stage IIB/IIC and Stage III melanoma.
- In unresectable or metastatic Stage IV melanoma, dual checkpoint blockade with nivolumab plus ipilimumab (CheckMate 067) delivers a landmark 7.5-year overall survival of 48% and median OS of 72.1 months; fixed-dose nivolumab plus relatlimab (Opdualag, targeting PD-1 and LAG-3) provides superior PFS over anti-PD-1 monotherapy with reduced toxicity.
- For treatment-naive BRAF V600-mutated metastatic melanoma, the randomized Phase 3 DREAMseq trial established that initiating frontline nivolumab plus ipilimumab followed by salvage BRAF/MEK inhibition yields significantly superior 2-year overall survival (72% vs 52%) compared to the reverse sequence.
- Advanced Basal Cell Carcinoma (BCC) is targeted with oral Hedgehog pathway / Smoothened (SMO) inhibitors (vismodegib, sonidegib), requiring pharmacist management of class-defining muscle spasms, alopecia, dysgeusia, and strict embryofetal teratogenicity safeguards.
- Locally advanced or metastatic Cutaneous Squamous Cell Carcinoma (cSCC) responds robustly to anti-PD-1 checkpoint inhibition (cemiplimab, pembrolizumab), driven by high ultraviolet-induced tumor mutational burden; Merkel Cell Carcinoma is managed frontline with anti-PD-(L)1 immunotherapy (avelumab, pembrolizumab).
9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
Cutaneous malignancies comprise a spectrum ranging from highly prevalent, slow-growing keratinocyte carcinomas to aggressive, highly immunogenic melanocytic and neuroendocrine neoplasms. Cutaneous Melanoma, while accounting for only ~1% of all skin cancers, causes the overwhelming majority of skin cancer deaths due to its early propensity for lymphatic and hematogenous metastasis.
Over the past fifteen years, cutaneous oncology has undergone an unprecedented therapeutic transformation driven by two breakthrough modalities: (1) Immune Checkpoint Blockade (targeting CTLA-4, PD-1, and LAG-3), and (2) MAPK Pathway Targeted Inhibition (dual BRAF + MEK small-molecule inhibitors). Similar breakthroughs in Non-Melanoma Skin Cancers (NMSC)—including Hedgehog pathway inhibition for Basal Cell Carcinoma (BCC) and anti-PD-1 immunotherapy for Cutaneous Squamous Cell Carcinoma (cSCC) and Merkel Cell Carcinoma (MCC)—have replaced morbid disfiguring surgeries and toxic cytotoxic regimens.
1. Cutaneous Melanoma: Pathophysiology, Staging, and Prognostic Factors
Melanoma arises from malignant transformation of epidermal melanocytes, heavily driven by ultraviolet (UV) radiation-induced DNA mutagenesis. The resulting genomic landscape exhibits the highest Tumor Mutational Burden (TMB) of all human cancers, creating abundant neoantigens that render melanoma exceptionally responsive to T-cell-directed immunotherapies.
+-----------------------------------------------------------------------------+
| MELANOMA STAGING & PROGNOSTIC ARCHITECTURE (AJCC 8TH) |
| |
| [PRIMARY TUMOR ATTRIBUTES (T-STAGE)] |
| - Breslow Thickness: Deepest vertical invasion in millimeters (mm) |
| * T1: <=1.0 mm (T1a: <0.8 mm without ulceration; T1b: 0.8-1.0 mm or ulc)|
| * T2: >1.0 to 2.0 mm | T3: >2.0 to 4.0 mm | T4: >4.0 mm |
| - Ulceration Status: Presence of epidermal breakdown (worsens prognosis) |
| |
| [SENTINEL LYMPH NODE BIOPSY (SLNB) INDICATIONS] |
| - Recommended for all T2-T4 lesions (>1.0 mm) and high-risk T1b lesions |
| (0.8-1.0 mm OR <0.8 mm with ulceration) |
| |
| [REGIONAL NODAL METASTASES (STAGE III)] |
| - Clinically occult (microscopic/SLNB-positive) vs. clinically macrometast|
| - In-transit, satellite, and microsatellite metastases |
| |
| [DISTANT HEMATOGENOUS METASTASES (STAGE IV)] |
| - M1a: Distant skin, subcutaneous, or distant lymph nodes (Normal LDH) |
| - M1b: Lung metastases (Normal LDH) |
| - M1c: Non-CNS visceral metastases (GI, liver, spleen, bone) (Normal LDH) |
| - M1d: Central Nervous System (Brain/Spinal Cord) Metastases |
| * Suffix (1): Elevated Serum Lactate Dehydrogenase (LDH) across M1a-M1d |
| (Serum LDH is an independent, powerful negative prognostic biomarker) |
+-----------------------------------------------------------------------------+
2. Adjuvant Therapy for Resected High-Risk Melanoma
Surgical excision with histologically clear margins (1 cm margin for T1; 1–2 cm margin for T2; 2 cm margin for T3–T4) is curative for localized early disease. For high-risk resected disease, adjuvant therapy is administered for a planned duration of 1 year to eradicate microscopic micrometastases.
+-----------------------------------------------------------------------------+
| ADJUVANT THERAPY SELECTION IN RESECTED MELANOMA |
| |
| STAGE IIB / IIC (T3b / T4b Node-Negative): |
| - KEYNOTE-716: Pembrolizumab (200 mg Q3W or 400 mg Q6W) x 1 YEAR |
| - CheckMate 768: Nivolumab (240 mg Q2W or 480 mg Q4W) x 1 YEAR |
| ---> Reduces distant metastasis-free survival (DMFS) hazard by 36-40% |
| |
| STAGE III / IV RESECTED (Node-Positive or Resected Oligometastatic): |
| |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [BRAF V600E / V600K MUTATED] [BRAF WILD-TYPE] |
| - Option A: Anti-PD-1 Immunotherapy - Anti-PD-1 Monother: |
| * Nivolumab x 1 Year (CheckMate 238) * Nivolumab x 1 Yr |
| * Pembrolizumab x 1 Year (KEYNOTE-054) * Pembrolizumab x 1Y|
| - Option B: Targeted BRAF + MEK Inhibition |
| * Dabrafenib (150 mg BID) + Trametinib (2 mg Daily) x 1 Year (COMBI-AD) |
+-----------------------------------------------------------------------------+
Clinical Nuances: Adjuvant Immunotherapy vs. Targeted Therapy
- CheckMate 238 Trial: Randomized Phase 3 trial in resected Stage IIIB–IV melanoma comparing nivolumab (3 mg/kg Q2W x 1 year) versus high-dose ipilimumab (10 mg/kg Q3W x 4 doses, then Q12W). Nivolumab demonstrated significantly superior Recurrence-Free Survival (5-year RFS: 50% vs. 39%; HR 0.72) with a dramatically lower incidence of Grade 3/4 treatment-related adverse events (14% vs. 46%).
- KEYNOTE-054 Trial: Adjuvant pembrolizumab (200 mg Q3W x 1 year) in resected Stage III melanoma achieved a 40% reduction in recurrence or death (RFS HR 0.60).
- COMBI-AD Trial (Dabrafenib + Trametinib in BRAF V600+): Phase 3 trial in resected Stage III BRAF V600E/K-mutated melanoma. One year of adjuvant dabrafenib plus trametinib demonstrated durable relapse risk reduction (5-year RFS: 52% vs. 36%; HR 0.51) and sustained overall survival advantage (OS HR 0.80).
- Decision Rationale: Adjuvant targeted therapy provides immediate, rapid protection against early relapse but risk recurs after discontinuation. Adjuvant immunotherapy induces immunological memory with a characteristic long-term survival plateau ("tail on the curve").
3. Unresectable Stage III & Metastatic Stage IV Cutaneous Melanoma
Systemic management of advanced melanoma depends on BRAF V600 mutation status, tempo of disease progression, presence of brain metastases, and baseline performance status.
+-----------------------------------------------------------------------------+
| METASTATIC MELANOMA SYSTEMIC THERAPY PARADIGMS |
| |
| 1. DUAL CHECKPOINT BLOCKADE: NIVOLUMAB + IPILIMUMAB (CheckMate 067) |
| - Induction: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg IV Q21D x 4 DOSES |
| - Maintenance: Nivolumab 240 mg Q2W (or 480 mg Q4W) until progression |
| - Landmark Results: 7.5-Year Overall Survival 48%; mOS 72.1 MONTHS! |
| - Superiority in Brain Metastases: Intracranial ORR ~55% (CheckMate 204)|
| - Trade-Off: Severe Grade 3/4 irAEs in 59% (requires aggressive manage)|
| |
| 2. DUAL CHECKPOINT BLOCKADE: NIVOLUMAB + RELATLIMAB (RELATIVITY-047) |
| - Fixed-Dose Combination: Nivolumab 480 mg + Relatlimab 160 mg IV Q4W |
| - Targets: PD-1 (Nivolumab) + LAG-3 (Relatlimab) |
| - Results: Median PFS 10.1 vs 4.6 months over Nivolumab alone (HR 0.75)|
| - Safety: Grade 3/4 AEs ~21% (substantially less toxic than Nivo/Ipi) |
| |
| 3. ANTI-PD-1 MONOTHERAPY (Pembrolizumab or Nivolumab) |
| - Category 1 option for frail patients or severe autoimmune risk |
| |
| 4. TARGETED BRAF + MEK INHIBITION (BRAF V600E/K Mutated Only) |
| - Encorafenib (450 mg Daily) + Binimetinib (45 mg BID) [COLUMBUS Trial]|
| - Dabrafenib (150 mg BID) + Trametinib (2 mg Daily) [COMBI-d/v] |
| - Vemurafenib (960 mg BID) + Cobimetinib (60 mg D1-21) [coBRIM] |
| - High ORR (>65-70%), rapid symptom relief; mPFS ~12-15 months |
+-----------------------------------------------------------------------------+
The DREAMseq Trial & Optimal Treatment Sequencing
In patients harboring BRAF V600E/K mutations, the randomized Phase 3 DREAMseq (ECOG-ACRIN EA6134) trial addressed whether to start with immunotherapy or targeted therapy:
- Step 1: Frontline Nivolumab + Ipilimumab -> Step 2 (upon progression): Dabrafenib + Trametinib
- Versus Step 1: Frontline Dabrafenib + Trametinib -> Step 2 (upon progression): Nivolumab + Ipilimumab
- Landmark Finding: Starting with Nivolumab + Ipilimumab yielded a 2-year Overall Survival of 72% compared to only 52% when starting with targeted therapy (p = 0.010). The trial established that upfront immunotherapy is the preferred first-line standard for asymptomatic or minimally symptomatic BRAF-mutated melanoma, reserving BRAF/MEK inhibitors for second-line or rapid visceral crisis situations.
Comparative Matrix: FDA-Approved Dual BRAF + MEK Regimens
| Regimen | Component Dosing & Schedule | Storage & Administration | Signature Toxicities & Monitoring Protocol |
|---|---|---|---|
| Encorafenib + Binimetinib | Encorafenib 450 mg PO Daily + Binimetinib 45 mg PO BID | Take with or without food. Room temperature storage. | Lowest pyrexia rate (18–20%). Serous retinopathy / Retinal Pigment Epithelial Detachment (RPED), LVEF decline, elevated CPK, arthralgias. |
| Dabrafenib + Trametinib | Dabrafenib 150 mg PO BID + Trametinib 2 mg PO Daily | Take on an empty stomach (1 hr before or 2 hr after food). Trametinib MUST BE REFRIGERATED (2–8°C). | Severe Pyrexia Syndrome (55–60%): chills, rigors, hypotension. Hold dabrafenib; resume upon resolution; use oral prednisone 10 mg daily for recurrent fevers. RPED, LVEF decline. |
| Vemurafenib + Cobimetinib | Vemurafenib 960 mg PO BID + Cobimetinib 60 mg PO Daily (Days 1–21 of 28d cycle) | Take with or without food. Cobimetinib is a 21-day on / 7-day off cycle. | Severe Photosensitivity & Sunburn (Grade >=3 in 30%): mandatory broad-spectrum UV protection. QTc interval prolongation, hepatotoxicity, CPK elevation. |
4. Advanced & Novel Immunotherapeutic Modalities in Melanoma
+-----------------------------------------------------------------------------+
| SPECIALIZED IMMUNOTHERAPEUTICS IN MELANOMA |
| |
| 1. LIFILEUCEL (Amtagvi) [Autologous Tumor-Infiltrating Lymphocytes (TIL)] |
| - Indication: Refractory metastatic melanoma progressing on anti-PD-1 |
| and BRAF/MEK inhibitors. |
| - Process: Surgical tumor harvest -> Ex-vivo TIL expansion with IL-2 ->|
| Non-myeloablative lymphodepletion (Cyclophosphamide 60 mg/kg x 2d + |
| Fludarabine 25 mg/m2 x 5d) -> Single TIL infusion -> High-dose IL-2 |
| (aldesleukin 600,000 IU/kg IV Q8H for up to 6 doses). |
| - Efficacy: Objective response rate ~31.4%; durable >2-year responses. |
| |
| 2. TALIMOGENE LAHERPAREPVEC (T-VEC) [Intralesional Oncolytic HSV-1] |
| - Genetically modified Herpes Simplex Virus-1 encoding human GM-CSF. |
| - Directly injected into unresectable cutaneous, subcutaneous, and |
| nodal lesions. Lyses tumor cells and releases neoantigens. |
| - Biosafety: Healthcare personnel must wear gloves/gowns. Avoid in |
| immunocompromised or pregnant individuals. |
| |
| 3. TEBENTAFUSP (Kimmtrak) [ImmTAC Bispecific gp100 x CD3 Fusion] |
| - Indication: HLA-A*02:01-positive unresectable or metastatic UVEAL |
| Melanoma (Phase 3 IMCgp100-202 Trial; OS HR 0.51 vs investigator rx).|
| - Mechanism: Soluble T-cell receptor targeting melanocyte gp100 peptide|
| presented on HLA-A*02:01 linked to anti-CD3 scFv. |
| - Dosing: Step-up weekly IV (Day 1: 20 mcg, Day 8: 30 mcg, Day 15+: 68 |
| mcg); mandatory inpatient monitoring for Cytokine Release Syndrome. |
+-----------------------------------------------------------------------------+
5. Non-Melanoma Skin Cancers (BCC, cSCC, and Merkel Cell Carcinoma)
Basal Cell Carcinoma (BCC)
Basal Cell Carcinoma accounts for ~80% of all non-melanoma skin cancers. The primary oncogenic driver is aberrant activation of the Hedgehog (Hh) Signaling Pathway, predominantly through loss-of-function mutations in the tumor suppressor PATCHED1 (PTCH1) (90%) or activating mutations in SMOOTHENED (SMO) (10%).
+-----------------------------------------------------------------------------+
| HEDGEHOG PATHWAY PHARMACOLOGY IN BCC |
| |
| [PHYSIOLOGICAL PATHWAY] |
| - Unbound PTCH1 constitutively inhibits transmembrane SMO on primary cilia|
| - Sonic Hedgehog (SHH) ligand binds PTCH1 -> releases SMO inhibition |
| - Activated SMO triggers GLI1/GLI2 nuclear transcription factor translocation|
| |
| [ONCOGENIC DEREGULATION IN BCC] |
| - Loss of PTCH1 -> Constitutive SMO activation -> Uncontrolled basal cell |
| proliferation and invasiveness. |
| |
| [TARGETED SMO INHIBITORS] |
| - VISMODEGIB: 150 mg PO ONCE DAILY (ERIVANCE Trial) |
| - SONIDEGIB: 200 mg PO ONCE DAILY on an EMPTY STOMACH (BOLT Trial) |
| |
| [CLASS-EFFECT TOXICITIES & CLINICAL MANAGEMENT] |
| - Muscle Spasms (70-75%): Manage with cyclobenzaprine, baclofen, calcium |
| channel blockers (amlodipine), or planned treatment breaks. |
| - Alopecia (60-65%) & Dysgeusia/Ageusia (55-60% -> severe weight loss) |
| - BOXED WARNING FOR EMBRYOFETAL TOXICITY: Severe teratogenicity / fetal |
| death; mandatory negative pregnancy test within 7 days prior and strict |
| contraception during and for 24 months (vismodegib) post-therapy. |
| - Second-Line Option: Cemiplimab 350 mg Q3W for SMO-refractory BCC. |
+-----------------------------------------------------------------------------+
Cutaneous Squamous Cell Carcinoma (cSCC)
Cutaneous Squamous Cell Carcinoma accounts for ~20% of skin cancers. Advanced, unresectable, or metastatic cSCC harbors an extraordinarily high UV-induced mutation burden, making it uniquely vulnerable to PD-1 checkpoint inhibition.
- Cemiplimab (EMPOWER-CSCC-1 Trial): Recombinant human anti-PD-1 monoclonal antibody administered at 350 mg IV every 3 weeks. Achieved an Objective Response Rate (ORR) of 46–50% with durable remissions exceeding 24 months.
- Pembrolizumab (KEYNOTE-629 Trial): Approved at 200 mg IV Q3W or 400 mg IV Q6W for recurrent or metastatic cSCC not curable by radiation or surgery, demonstrating an ORR of 35–50%.
Merkel Cell Carcinoma (MCC)
Merkel Cell Carcinoma is an aggressive cutaneous neuroendocrine carcinoma driven by Merkel Cell Polyomavirus (MCPyV) large T-antigen integration (~80% of cases in North America) or extensive UV-induced somatic mutations (~20%). It is characterized by rapid nodal metastasis and historical poor outcomes with cytotoxic chemotherapy.
- Avelumab (JAVELIN Merkel 200 Trial): Fully human anti-PD-L1 IgG1 antibody dosed at 800 mg IV every 2 weeks (premedicated with antihistamine and acetaminophen). First FDA-approved therapy for metastatic MCC, demonstrating an ORR of 33–40% with high durability.
- Pembrolizumab (KEYNOTE-017): First-line therapy in advanced MCC demonstrating an ORR of 56–58% and 2-year overall survival of ~69%.
- Retifanlimab: Anti-PD-1 monoclonal antibody approved at 500 mg IV every 4 weeks for metastatic or recurrent locally advanced MCC.
6. Summary Comparison of Cutaneous Therapeutics
| Disease Subtype | Setting / Molecular Target | Standard-of-Care Pharmacotherapy | Landmark Trial & Primary Endpoint | Key Clinical Pharmacist Pearls | | :--- | :--- | :--- | :--- | | Cutaneous Melanoma | Stage IIB/IIC / Resected | Pembrolizumab 200 mg Q3W x 1 year | KEYNOTE-716 (RFS / DMFS benefit) | 1-year total duration; monitor thyroid/hypophysitis/colitis. | | Cutaneous Melanoma | Stage III Resected / BRAF+ | Dabrafenib + Trametinib x 1 year | COMBI-AD (5-yr RFS 52% vs 36%, HR 0.51) | Trametinib refrigeration; manage dabrafenib pyrexia. | | Cutaneous Melanoma | Metastatic / Frontline | Nivolumab + Ipilimumab x 4c -> Nivo | CheckMate 067 (7.5-yr OS 48%; mOS 72.1 mo) | High rate of Grade 3/4 irAEs (59%); superior in brain mets. | | Cutaneous Melanoma | Metastatic / Frontline | Nivolumab + Relatlimab (Opdualag) Q4W | RELATIVITY-047 (PFS 10.1 vs 4.6 mo, HR 0.75) | Dual PD-1 + LAG-3 inhibition; lower toxicity than Nivo/Ipi. | | Cutaneous Melanoma | Refractory / Post-PD-1 | Lifileucel (Amtagvi) + IL-2 | C-144-01 (ORR 31.4%) | Autologous TIL cellular therapy; inpatient high-dose aldesleukin rescue. | | Uveal Melanoma | Metastatic / HLA-A*02:01+ | Tebentafusp (Kimmtrak) IV weekly | IMCgp100-202 (OS HR 0.51) | gp100 x CD3 ImmTAC; mandatory inpatient CRS monitoring. | | Basal Cell Carcinoma | Locally Adv / Metastatic | Vismodegib 150 mg PO daily OR Sonidegib | ERIVANCE / BOLT (ORR ~43–58%) | SMO inhibitors; muscle spasms (70%), alopecia, teratogenicity. | | Squamous Cell Carcinoma | Locally Adv / Metastatic | Cemiplimab 350 mg Q3W OR Pembrolizumab | EMPOWER-CSCC-1 (ORR ~50%) | Checkpoint blockade; high UV mutational burden driver. | | Merkel Cell Carcinoma | Metastatic / Frontline | Avelumab 800 mg Q2W OR Pembrolizumab | JAVELIN Merkel 200 (ORR ~33–56%) | Anti-PD-(L)1 therapy replaces cytotoxic cisplatin/etoposide. |
A 52-year-old male with resected Stage IIIC (pT3bN2aM0) cutaneous melanoma undergoes molecular testing that confirms the presence of a BRAF V600E mutation. He has fully healed from a wide local excision and sentinel lymph node dissection with complete lymphadenectomy. In discussing adjuvant systemic therapy options to reduce the risk of disease recurrence, which of the following statements represents an accurate clinical comparison based on landmark clinical trials?
A 48-year-old female presents with newly diagnosed, treatment-naive unresectable metastatic cutaneous melanoma (Stage IV M1c). Molecular testing confirms a BRAF V600E mutation, normal serum LDH, and an ECOG performance status of 0 without cerebral metastases. According to the Phase 3 randomized DREAMseq (ECOG-ACRIN EA6134) trial, what is the optimal sequence of systemic therapies?
A 71-year-old male with locally advanced, unresectable Basal Cell Carcinoma of the scalp is initiated on vismodegib 150 mg orally once daily. After 6 weeks of therapy, he presents with severe, painful lower extremity muscle spasms occurring multiple times daily, moderate dysgeusia, and diffuse thinning of scalp hair (alopecia). What is the molecular target of vismodegib, and what is the standard clinical pharmacist approach to managing these class-defining adverse effects?
A 56-year-old female with HLA-A*02:01-positive unresectable metastatic uveal melanoma with extensive hepatic metastases presents for systemic therapy. Standard cutaneous melanoma therapies (anti-PD-1, anti-CTLA-4) have historically yielded minimal efficacy in uveal melanoma. Which of the following novel immunotherapeutic agents is FDA-approved specifically for this condition, and what is its mechanism of action?